RePost/ IBAH Stock Write Up
IBAH PART 3
OFFICER AND DIRECTORS
Geraldine A. Henwood Chief Executive Officer and Director (principal executive
officer)
Leonard F. Stigliano Chief Financial Officer (principal financial and accounting officer)
Winston J. Churchill Chairman of the Board of Directors
Ernst-Gunter Afting MD Director
Victor J. Bauer Ph.D. Director
Edwin A. Bescherer, Jr. Director
Martyn D. Greenacre Director
Judith L. Hardardt Director
Sidney Jevons, Ph.D. Director
Sandra Panem Director
Richard L. Sherman Director
Officer and Directors Background:
Dr. Geraldina A Henwood born 1952. Occupational Background: 1973-74 attended
Neuman College, Aston, Pa. 1974-85 active with SmithKline Beckman Corporation
Philadelphia, Pa. 1977-78 attended Hahnemann Medical College, Philadelphia, Pa.
1985-present officer in IBAH Inc. Ms. Henwood has served as a director since
July, 1992 and has been the President and Chief Executive Officer of IBAH since
the Merger in April, 1994. She was the founder, Chairman of the Board, Chief
Executive Officer and President of Bio-Pharm from its inception in 1985 until
the date of the Merger. Prior to founding Bio-Pharm, Ms. Henwood held a variety
of management positions with predecessors of SmithKline Beecham Corporation.
Winston J Churchill born 1941. Occupational Background: 1990-Present CHB with
IBAH Inc from its inception in January, 1990. He has been President of Churchill
Investment Partners, Inc. ("CIP"), a private investment firm, since 1989. From
1984 to 1989, Mr. Churchill was a general partner of Bradford Associates, a
private investment firm in Princeton, New Jersey. Prior to that time, he practiced
law at the Philadelphia firm of Saul, Ewing, Remick & Saul for sixteen years and
was a member of the Executive Committee. Mr. Churchill received an M.A.in
Economics
from Oxford University, where he studied on a Rhodes Scholarship, and a J.D. from
Yale Law School. Mr. Churchill is also Chairman of the Board of Directors of Central
Sprinkler Corporation; and a director of Geotek Communications, Inc.,and Tescorp,
Inc.
John M. Cullen born 1938. Occupational Background: 1993-Present Mr.Culler has
been active in IBAH Inc. 1989-1993 Vice President of Smith Kline Beecham
Corporation. Has over 20 years experience in pharmaceuticals research and
development. Received a PhD in Biochemistry from Seton Hall University and a JD
Degree from Temple University, Philadelpia, Pa.
Dr. Afting has served as a director since June, 1996. From 1995 to the present, Dr.
Afting has been president of GSF -National Research Center for Environmental Health
- in Munich, one of the largest governmental research centers in Germany. He is a
member of the advisory committee "Science,Technology and Innovation (section
biotechnology)" to the German
Chancellor Kohl. Dr. Afting has also served as a Professor and Member of the
Medical
Faculty at the University of Gottingen from 1978 to the present. From 1993 to 1995,
Dr. Afting was President and Chief Executive Officer of Roussel UCLAF in Paris,
France, a subsidiary of Hoechst AG, Frankfurt, Germany. Dr.Afting held various
positions within Hoechst AG from 1988 to 1993, including Head of Pharmaceutical
Division and Chairman of Divisional Board, and Head of Worldwide Pharmaceutical
Research and Member of Divisional Pharma Board.
Dr. Afting received an M.D. and Ph.D. in Chemistry from the University of
Freiburg/Breisgau. Dr. Afting is a member of the Board of Directors of Medigen,
Morphosys, Sequenone, Prolifix and Titan Pharmaceuticals Inc.
Dr. Bauer has served as a director since the Merger in April,1994. In February, 1997,
Dr. Bauer became Executive Director, Iloperidone at Titan Pharmaceuticals Inc., the
parent company of Theracell, Inc. where Dr. Bauer serves as Chairman. Before he
assumed his role at Titan, Dr. Bauer had been a self-employed consultant to
companies in the pharmaceutical and biotechnology industries since December, 1992.
Prior to that time, Dr.Bauer was with
Hoechst-Houssel Pharmaceuticals Inc., where he served as President from 1988
through 1992. Dr. Bauer is a director and Trustee of the New Jersey Symphony
Orchestra, serving as Vice-Chairman of its Board. Dr. Bauer received aPh.D. in
Organic Chemistry from the University of Wisconsin.
Mr. Bescherer has served as a director since March, 1996. He spent 17 years at The
Dun & Bradstreet Corporation where he was the Chief Financial Officer for 14 years,
including the last eight years as an Executive Vice President. Prior to joining Dun &
Bradstreet, Mr. Bescherer spent twenty-three years at General Electric in a variety of
senior finance and management
roles.
Mr. Brunhofer has been the Corporate Controller of IBAH since December,1995
serving as the Principal Accounting Officer as well from June, 1996 to the present.
From the Merger in April, 1994 through December, 1995, Mr. Brunhofer held the
position of U.S. Controller of IBAH. From April, 1993 through the Merger, he was
the Controller of Bio-Pharm Clinical Services, Inc. From
1987 through 1993, he progressed from Staff Accountant, then Senior Accountant to
Audit Manager in the Philadelphia office of Arthur Andersen LLP. Mr. Brunhofer is a
certified public accountant.
Mr. Dillon has served as Executive Vice President, Worldwide Corporate
Development since January, 1997 and from June, 1995 through December, 1996 he
served as Executive Vice President, Worldwide Business Development. From June,
1994 to June, 1995 he served as Senior Vice President, Corporate Development.
Immediately prior to joining IBAH, Mr. Dillon served as CEO, Research Data
Corporation ("RDC"), a company providing data management and software
development services for the pharmaceutical industry. Mr. Dillon also served as Senior
Vice President, Corporate Development for RDC from 1991-1992. Prior to joining
RDC, Mr. Dillon was employed for 22 years at SmithKline Beecham Corporation and
its predecessors, most recently as Vice President, Worldwide Business Development
for the Pharmaceutical Division. Mr. Dillon received an M.B.A. from the Wharton
School at the University of Pennsylvania.
Mr. Greenacre has served as a director since the Merger in April,1994 and has been
President and Chief Executive Officer of Zynaxis, Inc., a therapeutics research firm,
since March, 1993. From July, 1989 through June, 1992, Mr. Greenacre was
Chairman - Europe Pharmaceuticals of
SmithKline Beecham plc. Health Care. Prior to that time, he was Vice President -
Europe
Pharmaceuticals for SmithKline Beecham Health Care. Mr. Greenacre serves on the
Board of Directors of Cephalon, Inc., Zynaxis, Inc., Creative Biomolecules, Inc. and
Genset, Inc.
Ms. Hardardt has served as a director since the acquisition of The Hardardt Group
("THG") on October 1, 1996. Ms. Hardardt was the founder of THG and has served
as its President since its inception in 1989. Prior to starting THG, Ms. Hardardt
worked as a consultant to the pharmaceutical industry and held a variety of
management positions with Janssen Pharmaceutica Inc.
Dr. Jackson has served as President of the U.S. CRO since September, 1996. From
the date of the Merger until he assumed the
position of
President, Dr. Jackson served as the Chief Medical Officer of the
Company. For a brief
period before the Merger he was President and Chief Executive Officer of
Affinity. From 1988 to 1994, Dr. Jackson held the position of Vice
President of Clinical Research with Janssen Research Foundation.
Dr. Jevons has served as a director since the Merger in April,
1994. Since the acquisition of EPIC by Bio-Pharm and the subsequent
Merger, Dr.
Jevons has served the Company as President of European operations,
Managing
Director, U.K. Operations, and, as of April 1, 1996, Chairman, U.K. and
Executive
Vice- President of International Development. Prior to that time, Dr.
Jevons was
the Managing Director of EPIC, which he co-founded in 1989. From 1985
until
1989, he held senior management positions, including Chief Operations
Officer, at a
major international CRO, Institute of Clinical Pharmacology. Prior to
that time,
he held senior positions in both research and product development with
Pfizer,
Inc. of the U.K. Dr. Jevons has a Ph.D. in biochemistry from the
University of
Liverpool.
Dr. Panem has served as a director since July, 1995. She is
currently the President of Vector Fund Management, L.P., the asset
management
affiliate of Vector Securities International, Inc., specializing in the
emerging life
sciences and health care industries. Prior to joining Vector Fund
Management in 1994, Dr. Panem served as Vice President and Portfolio
Manager for the
Oppenheimer Global BioTech Fund. Prior to Oppenheimer, Dr. Panem was
Vice
President at Salomon Brothers Venture Capital. She received a B.S. in
biochemistry and a Ph.D. in microbiology from the University of Chicago.
Dr. Panem serves as a director of Madek Biosciences Corp., Synaptic
Pharmaceutical Inc., Healthtech Services Corp. and Molecular Informatics
Inc.
Mr. Santoro has been responsible for the Pharmaceutics Division
of
IBAH since April, 1994 and currently holds the position of President,
Bio-Pharm
Pharmaceutics Services, Inc. Prior to the Merger, Mr. Santoro was Vice
President of Bio-Pharm Clinical Services. In that position he was
responsible for
data management and computer systems. From 1976 to 1987, he held various
consulting positions with a number of Fortune 500 companies related to
data management
and computer systems.
Mr. Sherman has served as a director since 1993. He is the
founding
principal of QED Technologies, a business consulting group founded in
November, 1992. He is also a Principal of CIP Capital Management, Inc.,
the general
partner of CIP Capital, L.P., a private investment fund. From 1976
through
June, 1989, Mr. Sherman held several positions with SmithKline Beecham
Corporation and its predecessors, including Deputy General Counsel.
Before founding QED,
Mr. Sherman was a partner with the firm of Pepper, Hamilton & Scheetz,
where
his practice focused on international and domestic commercial
transactions,
technology transfer and business counseling, with particular expertise
in
pharmaceuticals, medical devices, biotechnology and other healthcare
technologies. Mr. Sherman is member of the Board of Directors of Sparta
Pharmaceuticals, Inc.
Mr. Stigliano joined IBAH as Chief Financial Officer in June,
1995.
>From 1991 until the time he joined the Company, Mr. Stigliano had been
Chief
Financial Officer of Chemex Pharmaceuticals, Inc., a pharmaceutical
development company specializing in dermatology research. Prior to that
time Mr.
Stigliano spent nine years with Technicon Instruments Corporation, Inc.,
a diagnostic
company which developed and marketed blood analyzers for clinical
laboratories where he held several positions including Senior Vice
President, Finance &
Business Development and President, North America.
EQUITY
Common $.01 Par, 8/97, 50M auth., 23,103,562 issd. Insiders own 44%. 6 others
own a total of 38%. IPO: 4/92, 2,166,667 shs. @ $6 by Pennsylvania Merchant
Group. 4/94, issd. 8,828,655 shs. in Bio-Pharm merger. PO 4/96, 3M shs. @ $6.50.
LTD: $1.8M @ Prime + .75% - 2%, $242K @ 7.5%, $1.2M in leases. Preferred
$.01 Par, 2M auth., 749,665 issd. At 9/30/97 27.4 million common equivalents
outstanding |
